A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block

Conditions:   Asthma;   Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: Budesonide;   Drug: Formoterol
Sponsor:   Intech Biopharm Ltd.
Completed – verified July 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.